<DOC>
	<DOCNO>NCT00452803</DOCNO>
	<brief_summary>It suggest bimodal trimodal approach combine neoadjuvant chemotherapy without radiotherapy follow surgery provide potentially superior method enhance resectability improve locoregional control survival compare radiotherapy alone follow surgery . Unsolved question identification best induction strategy , impact surgery long-term survival , contribution radiation therapy set . Thus , investigator conduct phase II trial compare neoadjuvant chemotherapy concurrent chemoradiotherapy patient biopsy proven N2 stage IIIA NSCLC address optimal induction strategy .</brief_summary>
	<brief_title>Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy N2 Positive IIIA Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Preoperative Therapy Arm 1 . ( preoperative chemotherapy ) Paclitaxel ( 90 mg/m2 ) day 1 8 Cisplatin ( 40 mg/m2 ) day 1 8. q 3 week , 2 cycle Arm 2 . ( preoperative chemoradiotherapy ) Paclitaxel ( 50 mg/m2 ) day 1 , 8 , 15 , 22 &amp; 29 Cisplatin ( 20 mg/m2 ) day 1 , 8 , 15 , 22 &amp; 29 . Thoracic radiation therapy ( TRT ) 1.8 Gy daily , five time per week ( 45 Gy target dose 5 week ) . Postoperative Consolidation Chemotherapy : Paclitaxel ( 90 mg/m2 ) day 1 8 . Cisplatin ( 40 mg/m2 ) day 1 8. q 3weeks , 2 cycle</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis nonsmall cell lung cancer . 2 . Presence biopsyproven N2 stage IIIA , accord American Joint Committee Cancer ( AJCC ) , none mediastinal lymph node &gt; 3 cm large diameter . 3 . Tumor amenable surgical resection . 4 . At least one unidimensional measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST . 2000 ) . 5 . No prior tumor therapy ( surgery , radiotherapy , chemotherapy , immunotherapy , type tumor therapy ) . 6 . Performance status 01 ECOG scale . 7 . At least 18 year old . 8 . Patient compliance allow adequate followup . 9 . Medical fitness patient adequate radical NSCLC surgery . 10 . Adequate organ function include follow : Adequate hematologic function : WBC count ≥ 4,000/uL , absolute neutrophil count ( ANC ) ≥ 1,500/uL , platelet count ≥ 100,000/uL , hemoglobin ≥ 10 gm/dL.Adequate hepatic function : bilirubin ≤ 1.5 x UNL , ALT AST ≤ 2.5 x UNL.Adequate renal function : creatinine ≤ 1.5mg/dL . 11 . Signed informed consent patient legal representative.12 . Patients reproductive potential must use approved contraceptive method 3 month study . Females childbearing potential must negative urine hCG test within 7 day prior study enrollment . 1 . Concurrent administration tumor therapy , include radiotherapy , chemotherapy , immunotherapy . 2 . Active uncontrolled infection . 3 . Serious concomitant disorder would compromise safety patient compromise patient 's ability tolerate therapy . 4 . MI within precede 6 month symptomatic heart disease include unstable angina , congestive heart failure , uncontrolled arrhythmia . 5 . Significant neurological mental disorder . 6 . Second primary malignancy . 7 . Pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Non small cell lung cancer</keyword>
</DOC>